A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 24 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jan 2018.
- 12 Jan 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Jan 2018.